CytoMed Therapeutics Limited Ordinary Shares (GDTC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.78 (-12.23%), Market cap $0.01B, 52-week low–high $0.72 ~ $2.69.
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the p
Financial statements, price targets, institutional (13F) holdings and related news for CytoMed Therapeutics Limited Ordinary Shares are updated in real time on BlackAll Trade.
CytoMed Therapeutics Limited Ordinary Shares trades at $0.78 (-12.23%). Real-time quotes and charts are available on BlackAll Trade.
CytoMed Therapeutics Limited Ordinary Shares has a market cap of about $0.01B.
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysi